FIG. 2.

β7 expression on HSCs enhances engraftment potential. (A) Experimental design of competitive reconstitution assay using CD150⁺β7⁺ and CD150⁺β7⁻ LSK BM cells. (B) Frequency of donor-derived myeloid cells in the peripheral blood of recipient mice at 16 weeks after transplantation (n = 9 per group, from three independent experiments, *P < 0.05). (C) Lethally irradiated mice were transplanted with 500 WT or β7KO HSCs and their survival was monitored (n = 8–9 per group, from two independent experiments, *P < 0.05). (D) Experimental design of competitive reconstitution assay using wild type (WT) and β7KO HSCs. (E) Frequency of donor-derived myeloid cells in the peripheral blood of recipient mice between 4 and 16 weeks after transplantation. Data are mean ± SEM (n = 11–17 per group, from four independent experiments, *P < 0.05).